Brid M. Ryan, Ph.D., M.P.H.
Dr. Ryan was among the first to demonstrate asymmetric division of DNA in cancer. This process is thought to underpin how tumors self-renew and regenerate. Since then, her studies have examined the roles of the tumor microenvironment and p53 in regulating this process in lung cancer.
Her lab oversees an integrative and translational approach to lung cancer research, examining the genetic, environmental, and biological contributions to racial disparities in lung cancer incidence. Her research program also develops biomarkers for the early detection of lung cancer.
Our research program addresses several unanswered questions in lung cancer using an approach that integrates epidemiological, experimental and translational research. Disparities in lung cancer incidence, especially amongst men, have been evident for several decades. However, the potential etiological, genetic, and biological reasons behind these differences are underexplored and not well understood. Our laboratory investigates the science behind these health disparities and is using a multidisciplinary approach to address this question. Our laboratory is also interested in applying a biological framework to understanding the mechanism of interaction between genetics and environment with regard to lung carcinogenesis. Specifically, we have an interest in both early and adult life exposures and mechanistically understanding how they mediate lung cancer risk later in life.
Selected Key Publications
A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.J Thoracic Oncol. 9: 1494-503, 2014. [ Journal Article ]
Evidence that the lung adenocarcinoma EML4-ALK fusion gene is not caused by exposure to secondhand tobacco smoke during childhood.Cancer Epidemiol. Biomarkers Prev. 23: 1432-4, 2014. [ Journal Article ]
- Mol. Cancer. 12: 139, 2013. [ Journal Article ]
- Proc. Natl. Acad. Sci. U.S.A. 107: 2195-200, 2010. [ Journal Article ]
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.Ann. Oncol. 17: 597-604, 2006. [ Journal Article ]
Dr. Ryan completed her undergraduate training in biochemistry at University College Cork, Ireland, in 2001. She received her Ph.D in Cancer Biology from University College Dublin and in 2006 was accepted into the NCI Cancer Prevention Fellowship Program. In 2007, she completed a Masters of Public Health at University College Dublin. She worked under the mentorship of Dr Curtis Harris during her postdoctoral training at the National Cancer Institute. In 2013, she became an NCI Earl Stadtman tenure track investigator at the NCI.
|Claire Meaney Ph.D.||Postdoctoral Fellow (Visiting)|
|Khadijah Aisha Mitchell M.Sc., Ph.D.||Special Volunteer|
|Sanju Sinha B.S.||Postbaccalaureate Fellow (CRTA)|
|Leila Toulabi Ph.D.||Postdoctoral Fellow (CRTA)|
|Adriana Zingone M.D., Ph.D.||Biologist|